Mylotarg (gemtuzumab ozogamicin) is a medication used in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML). It is a monoclonal antibody-drug conjugate that targets CD33, a protein found on the surface of leukemia cells.
Mechanism of Action: Mylotarg consists of an antibody that targets CD33, a protein expressed on the surface of leukemia cells, linked to a cytotoxic agent called calicheamicin. When Mylotarg binds to CD33 on leukemia cells, it is internalized into the cell, where calicheamicin is released. Calicheamicin then binds to DNA, causing breaks in the DNA strands and leading to cell death.
Benefits: The benefits of Mylotarg include:
- Treatment of newly diagnosed CD33-positive AML in combination with chemotherapy.
- Treatment of relapsed or refractory CD33-positive AML as a single agent.
- Improvement in overall response rates and survival outcomes in clinical trials.
- Potential for increased rates of complete remission and minimal residual disease negativity.
Dosage and Administration: Mylotarg is administered intravenously (IV) as an infusion. The recommended dosage and administration schedule may vary depending on the specific treatment regimen, patient characteristics, and treatment response. Healthcare professionals typically determine the appropriate dose and infusion schedule.
Suitability: Mylotarg is indicated for patients with CD33-positive AML, and its suitability for an individual patient is determined based on factors such as disease subtype, CD33 expression, prior treatments received, overall health status, and any underlying medical conditions.
Availability and Pricing: Mylotarg is available by prescription only and is typically administered in medical facilities equipped to administer IV medications, such as hospitals or infusion centers. Pricing can vary between countries and regions, and specific pricing information would need to be obtained from pharmaceutical databases, local pharmacies, or healthcare providers.
Mylotarg represents an important treatment option for patients with CD33-positive AML, particularly for those who have relapsed or refractory disease. However, like all medications, it may cause side effects, and patients should be closely monitored by healthcare professionals during treatment.
MYLOTARG 5 MG 1X20ML IV FLAKON